Vimarsana
Biggest News Aggregation in the World

Igard Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Igard Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Igard Study Today - Breaking & Trending Today

Budesonide Reduces eGFR Decline, Effect Could Prevent Clinical Events in IgA Nephropathy - Vimarsana News

Budesonide Reduces eGFR Decline, Effect Could Prevent Clinical Events in IgA Nephropathy

Published: November 4, 2023

Data for a pair of studies presented at Kidney Week 2023 provide an overview of the effects of eGFR and how this might translate to potential long-term benefit in patients IgA nephropathy.

Source: hcplive.com
Related Topics:
United StatesRichard LafayetteJonathan BarrattUniversity Of LeicesterStanford Glomerular Disease CenterAlnylam PharmaceuticalsAmerican Society Of Nephrology Kidney WeekAmerican SocietyNephrology Kidney WeekIgard StudyKidney WeekMayer ProfessorRenal MedicineLeicester GeneralCalliditas TherapeuticsTravere TherapeuticsChinook TherapeuticsIga Nephropathy TreatedYear Nefigard PhasePaper PresentedNefigard Two YearSlope Predicts Long Term Clinical BenefitReal World Iga NephropathyPriority ReviewAsn Kidney Week
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (1) - Vimarsana News

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (1)

Published: August 15, 2023

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United StatesUnited KingdomJonathanm BarrattUnited States Federal Drug AdministrationEuropean Union Member StatesUniversity Of LeicesterEuropean CommissionExchange CommissionNasdaq StockholmIgard StudyPrimary IgaMayer ProfessorRenal MedicineChief Executive OfficerInvestor RelationsFull PrescribingIga NephropathyPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform Act
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet - Vimarsana News

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Published: August 15, 2023

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesJonathanm BarrattEuropean CommissionExchange CommissionUnited States Federal Drug AdministrationUniversity Of LeicesterEuropean Union Member StatesNasdaq StockholmIgard StudyPrimary IgaMayer ProfessorRenal MedicineChief Executive OfficerInvestor RelationsFull PrescribingIga NephropathyPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActCalliditas Therapeutics
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (2) - Vimarsana News

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (2)

Published: August 15, 2023

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United KingdomUnited StatesJonathanm BarrattUniversity Of LeicesterEuropean Union Member StatesUnited States Federal Drug AdministrationEuropean CommissionExchange CommissionNasdaq StockholmIgard StudyPrimary IgaMayer ProfessorRenal MedicineChief Executive OfficerInvestor RelationsFull PrescribingIga NephropathyPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform Act